AMENDMENTS TO THE CLAIMS

This listing of claims will replace all prior versions, and listings of claims in the application:

Claim 1: (Cancelled):

Claim 2 (Cancelled):

Claim 3 (Cancelled):

Claim 4 (Currently amended): The adenovirus vector of claim [[1 or 3]] 5, 6, or 7, wherein the adenovirus vector further comprises an AAV *cap* gene.

Claim 5 (Currently amended): An adenovirus vector for the manufacture of rAAV, wherein the adenovirus vector comprises an AAV *rep* gene, and wherein the AAV p5 promoter is deleted upstream of the AAV rep gene and said vector contains a minimal promoter in place of the p5 promoter, wherein the minimal promoter ~~essentially~~ contains a TATA box as its only regulatory element.

Claim 6 (Previously presented): An adenovirus vector for the manufacture of rAAV, wherein the adenovirus vector comprises an AAV *rep* gene, and wherein the AAV p5 promoter is deleted upstream of the AAV rep gene and said vector contains a minimal Drosophila heat shock promoter in place of the p5 promoter.

Claim 7 (Previously presented): An adenovirus vector for the manufacture of rAAV, wherein the adenovirus vector comprises an AAV *rep* gene, and wherein the AAV p5 promoter is deleted upstream of the AAV rep gene and said vector contains a minimal adenoviral E1b promoter in place of the p5 promoter.

Claim 8 (Original): The adenovirus vector of claim 4, wherein the *rep* gene and the *cap* gene are inserted in place of at least a portion of one or more of the E1, E3 or E4 genes of adenovirus in a locus of the adenovirus vector.

Claim 9 (Original): The adenovirus vector of claim 8, wherein both the *rep* gene and the *cap* gene are inserted within the same locus of the adenovirus vector.

Claim 10 (Original): The adenovirus vector of claim 8, wherein the *rep* gene and the *cap* gene are inserted within different loci of the adenovirus vector.

Claim 11 (Previously presented): The adenovirus vector of claim 4, wherein the *rep* and *cap* genes are from different AAV serotypes.

Claim 12 (Currently amended): A method for producing recombinant rAAV, comprising the steps of:

a) infecting a host cell comprising a rAAV genome with the adenovirus vector according to claim [[1, 3,]] 5, 6 or 7;

b) growing the host cells under conditions in which rAAV is produced; and

c) optionally collecting the rAAV from the host cells.

Claim 13 (Original): The method according to claim 12, wherein the rAAV genome is stably integrated in a chromosome of the host cells.

Claim 14 (Previously presented): The method according to claim 12, wherein the host cell comprises an adenovirus vector comprising the rAAV genome and said host cell is co-infected with the adenovirus vector comprising the *rep* gene.

Claim 15 (Previously presented): The method according to claim 12, wherein the adenovirus vector provides a helper function for rAAV production.

Claim 16 (Previously presented): The method according to claim 12, wherein the host cell is a 293 cell.

Claim 17 (Previously presented): The method according to claim 12, further comprising the step of purifying the rAAV.

Claim 18 (Original): The method according to claim 12, wherein the host cells are selected from CHO, BHK, MDCK, 10T1/2, WEHI cells, COS, BSC 1, BSC 40, BMT 10, VERO, WI38, MRC5, A549, HT1080, 293, B-50, 3T3, NIH3T3, HepG2, Saos-2, Huh7, HER, HEK, HEL, or HeLa cells.

Claim 19 (Withdrawn): A lysate or supernatant comprising the rAAV produced by the method according to claim 12.

Claim 20 (Withdrawn): A purified rAAV produced by the method according to claim 19.

Claim 21 (Withdrawn): A pharmaceutical composition comprising the rAAV according to claim 20 and further comprising a pharmaceutically acceptable carrier.

Claim 22 (Withdrawn): A method for transient or stable gene transfer of a desired transgene to a mammalian cell, comprising the step of infecting the mammalian cell with the rAAV according to claim 20.

Claim 23 (Withdrawn): The method according to claim 22, wherein said transient or stable gene transfer is for genetic immunization, correction of genetic defects or production of proteins *in vitro, in vivo,* or *ex vivo.*

Claim 24 (Previously presented): The vector according to claim 15, wherein said helper function is provided by at least one gene product selected from the group consisting of adenoviral genes E1A, E1B, E2A, E4orf6 and VAI, or at least one gene product selected from the group consisting of HSV type 1 genes UL5, UL8, UL52, and UL29.

Claim 25 (Currently amended): The adenovirus vector of claim [[1 or 3]] 5, 6, or 7, wherein transcription of the AAV *rep* gene is promoted less than 50% of wildtype P5 promoter in a cell into which it has been introduced.

Claim 26 (Currently amended): The adenovirus vector of claim [[1 or 3]] 5, 6, or 7, wherein transcription of the AAV *rep* gene is promoted less than 25% of wildtype P5 promoter in a cell into which it has been introduced.

Claim 27 (Currently amended): The adenovirus vector of claim [[1 or 3]] 5, 6, or 7, wherein transcription of the AAV *rep* gene is promoted less than 15% of wildtype P5 promoter in a cell into which it has been introduced.

Claim 28 (Currently amended): The adenovirus vector of claim [[1 or 3]] 5, 6, or 7, wherein transcription of the AAV *rep* gene is promoted less than 10% of wildtype P5 promoter in a cell into which it has been introduced.

Claim 29 (Previously presented): The adenovirus vector of claim 4, wherein the *rep* and *cap* genes are from the same AAV serotype.

Claim 30 (Currently amended): A method for producing recombinant rAAV, comprising the step of, growing a host cell comprising a rAAV genome and an adenovirus vector

according to claim [[1, 3,]] 5, 6 or 7 under conditions in which rAAV is produced; and optionally collecting the rAAV produced from the host cell.

Claim 31 (Currently amended): The adenovirus vector of claim ~~1or claim 3~~ 5, 6, or 7 wherein Rep78 and Rep68 are produced at much lower levels than Rep52 and Rep40 in a cell into which it has been introduced.